Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 26, Issue 33, 2008, Pages 5407-5415

  Heymach, John V ^b   Paz Ares, Luis ^b   De Braud, Filippo ^b   Sebastian, Martin ^b   Stewart, David J ^b   Eberhardt, Wilfried E E ^b   Ranade, Anantbhushan A ^b   Cohen, Graham ^b   Trigo, Jose Manuel ^b   Sandler, Alan B ^b   Bonomi, Philip D ^b   Herbst, Roy S ^b   Krebs, Annetta D ^b   Vasselli, James ^b   Johnson, Bruce E ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL; PLACEBO; VANDETANIB;

ADULT; AGED; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CENTRAL NERVOUS SYSTEM METASTASIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DYSPNEA; FATIGUE; FEMALE; HUMAN; HYPERTENSION; INSOMNIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PATIENT SAFETY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; THROMBOCYTOPENIA; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PIPERIDINES; QUINAZOLINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 56749102822     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.3138     Document Type: Article

References (32)

1. American Cancer Society: Cancer facts and figures, 2008. http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf
2. Boyle P, Dresler C: Preventing the lung cancer epidemic. Ann Oncol 16:1565-1566, 2005
3. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006
4. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237-2246, 2003
5. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149-2158, 2003
6. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
7. Thatcher N, Chang A, Parikh P, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537, 2005
8. Gatzemeier U, Pluzanska A, Szczesna A, et al: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25:1545-1552, 2007
9. Giaccone G, Herbst RS, Manegold C, et al: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 22:777-784, 2004
10. Herbst RS, Giaccone G, Schiller JH, et al: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2. J Clin Oncol 22:785-794, 2004
11. Herbst RS, Prager D, Hermann R, et al: TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892-5899, 2005
12. Herbst RS, O'Neill VJ, Fehrenbacher L, et al: Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 25:4743-4750, 2007
13. Wedge SR, Ogilvie DJ, Dukes M, et al: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62:4645-4655, 2002
14. Carlomagno F, Vitagliano D, Guida T, et al: ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62:7284-7290, 2002
15. Herbst RS, Heymach JV, O'Reilly MS, et al: Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 16:239-249, 2007
16. Taguchi F, Koh Y, Koizumi F, et al: Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ('Iressa')-sensitive and resistant xenograft models. Cancer Sci 95:984-989, 2004
17. Wu W, Onn A, Isobe T, et al: Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther 6:471-483, 2007
18. Holden SN, Eckhardt SG, Basser R, et al: Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 16:1391-1397, 2005
19. Tamura T, Minami H, Yamada Y, et al: A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 1:1002-1009, 2006
20. Heymach JV, Johnson BE, Prager D, et al: Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 25:4270-4277, 2007
21. James K, Eisenhauer E, Christian M, et al: Measuring response in solid tumors: Unidimensional versus bidimensional measurement. J Natl Cancer Inst 91:523-528, 1999
22. Common Toxicity Criteria for Adverse Events (CTCAE) v3.0. Online Instructions and Guidelines. http://www.fda.gov/cder/cancer/toxicityframe.htm
23. Horiike A, Kimura H, Nishio K, et al: Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer. Chest 131:1628-1634, 2007
24. Chemotherapy for non-small cell lung cancer: Non-small Cell Lung Cancer Collaborative Group. Cochrane Database Syst Rev 2:CD002139, 2000
25. Simon RM, Steinberg SM, Hamilton M, et al: Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol 19:1848-1854, 2001
26. Wittekind CH, Sobin LH: TNM Classification of Malignant Tumours. New York, NY, Wiley-Liss, 2002
27. Heymach JV, West H, Kerr R, et al: ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC: Results of the run-in phase of a two-part randomized Phase II study. Lung Cancer 49:S247, 2005 (suppl 2)
28. Hanrahan EO, Lin HY, Du DZ, et al: Correlative analyses of plasma cytokine/angiogenic factor (C/AF) profile, gender and outcome in a randomized, three-arm, phase II trial of first-line vandetanib (VAN) and/or carboplatin plus paclitaxel (CP) for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 25:407s, 2007 (suppl; abstr 7593)
29. Lilenbaum R, Axelrod R, Thomas S, et al: Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol 26:863-869, 2008
30. Bencardino K, Manzoni M, Delfanti S, et al: Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: Results and open issues. Intern Emerg Med 2:3-12, 2007
31. Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191, 2004
32. Eberhardt WEE, Korfee S, Johnson BE, et al: Vandetanib in advanced NSCLC: An ongoing clinical evaluation program. J Thorac Oncol 2:S467-S468, 2007 (suppl 4; abstr PD3-3-4)